A Phase 1 interventional study of Recombinant RSV Vaccine (CHO Cell) and Recombinant RSV Vaccine (CHO Cell) in Respiratory Syncytial Virus (RSV), sponsored by Yikang Biotech (Suzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Yikang Biotech (Suzhou) Co., Ltd. · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older
This is a single-center, randomized, blinded, placebo-controlled trial. A total of 128 trial participants aged 18 years and older will be enrolled: 64 trial participants aged 18-59 years and 64 trial participants aged 60 years and older. Each age stratum will be divided into four cohorts, for a total of eight cohorts: low-dose antigen cohorts, high-dose antigen cohorts , adjuvant-only cohorts, and low-dose antigen + adjuvant cohorts in the 18-59-year and 60-years-and-older strata.
Eligible trial participants in each cohort will be randomized 3:1 on Day 0 to receive one dose of investigational vaccine (low-dose antigen, high-dose antigen, adjuvant, or low-dose antigen + adjuvant) or placebo. Enrollment will proceed in the order of adults (18-59 years) to older adults (60 years and older), low dose to high dose, and antigen to adjuvant to antigen + adjuvant.
To ensure the safety of the study population, the first four trial participants enrolled in each cohort will be designated as sentinel trial participants and randomized 3:1 to investigational vaccine or placebo.
This is the only study on the registry with Yikang Biotech (Suzhou) Co., Ltd. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Trial participants meeting any of the following exclusion criteria may not be enrolled:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects aged 18-59 years will receive single dose of Recombinant RSV Vaccine (CHO Cell), by IM injection into the deltoid muscle of the upper arm.
Biological: Recombinant RSV Vaccine (CHO Cell)
Subjects aged 18-59 years will receive double dose of Recombinant RSV Vaccine (CHO Cell), by IM injection into the deltoid muscle of the upper arm.
Biological: Recombinant RSV Vaccine (CHO Cell)
Subjects aged 18-59 years will receive single dose of Adjuvant Suspension, by IM injection into the deltoid muscle of the upper arm.
Biological: Adjuvant Suspension
Subjects aged 18-59 years will receive single dose of Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension, by IM injection into the deltoid muscle of the upper arm.
Biological: Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension
Subjects aged 18-59 years will receive single dose of placebo, by IM injection into the deltoid muscle of the upper arm.
Biological: Saline solution
Subjects aged ≥60 years will receive single dose of Recombinant RSV Vaccine(CHO Cell), by IM injection into the deltoid muscle of the upper arm.
Biological: Recombinant RSV Vaccine (CHO Cell)
Subjects aged ≥60 years will receive single dose of Recombinant RSV Vaccine(CHO Cell), by IM injection into the deltoid muscle of the upper arm.
Biological: Recombinant RSV Vaccine (CHO Cell)
Subjects aged ≥60 years will receive single dose of Adjuvant Suspension, by IM injection into the deltoid muscle of the upper arm.
Biological: Adjuvant Suspension
Subjects aged ≥60 years will receive single dose of Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension, by IM injection into the deltoid muscle of the upper arm.
Biological: Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension
Subjects aged ≥60 years will receive single dose of placebo, by IM injection into the deltoid muscle of the upper arm.
Biological: Saline solution
0.4 mL per dose
0.8 mL per dose
0.9 mL per dose
Drug page: CHO cell
0.9 mL per dose
0.9 mL per dose
Incidence of immediate adverse events
Incidence of all adverse events within 30 minutes after vaccination
Time frame: Within 30 minutes after vaccination
Incidence of solicited AEs
Incidence of solicited (local and systemic) adverse events within 14 days after vaccination
Time frame: Within 0-14 days after vaccination
Incidence of unsolicited AEs
Incidence of unsolicited adverse events within 30 days after vaccination
Time frame: Within 30 days after vaccination
Incidence of clinically significant abnormalities in clinical laboratory tests
Incidence of clinically significant abnormal laboratory test results on Day 4 after vaccination
Time frame: 4 days after vaccination
Incidence of clinically significant abnormal findings on 12-lead electrocardiograms
Incidence of clinically significant abnormal findings on 12-lead electrocardiograms on Days 4, 14, and 30 after vaccination
Time frame: 4 days, 14 days, 30 days after vaccination
Occurrence of serious adverse events (SAEs)
Occurrence of serious adverse events (SAEs) within 24 months after vaccination
Time frame: Within 24 months after vaccination
Occurrence of adverse events of special interest (AESIs)
Occurrence of adverse events of special interest (AESIs) within 12 months after vaccination
Time frame: Within 12 months after vaccination
GMT of Neutralizing Antibody against RSV serotype A and B
Measured by plaque reduction neutralization test (PRNT)
Time frame: 30 days after vaccination
GMFR of Neutralizing Antibody against RSV serotype A and B
Measured by plaque reduction neutralization test (PRNT)
Time frame: 30 days after vaccination
SCR of Neutralizing Antibody against RSV serotype A and B
Measured by plaque reduction neutralization test (PRNT)
Time frame: 30 days after vaccination
GMC of pre-F protein-binding antibodies
Measured by enzyme-linked immunosorbent assay(ELISA)
Time frame: 30 days after vaccination
GMFR of pre-F protein-binding antibodies
Measured by enzyme-linked immunosorbent assay(ELISA)
Time frame: 30 days after vaccination
SCR of pre-F protein-binding antibodies
Measured by enzyme-linked immunosorbent assay(ELISA)
Time frame: 30 days after vaccination
GMT of Neutralizing Antibody against RSV serotype A and B
Measured by plaque reduction neutralization test (PRNT)
Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination
GMFR of Neutralizing Antibody against RSV serotype A and B
Measured by plaque reduction neutralization test (PRNT)
Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination
SCR of Neutralizing Antibody against RSV serotype A and B
Measured by plaque reduction neutralization test (PRNT)
Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination
GMC of pre-F protein-binding antibodies
Measured by enzyme-linked immunosorbent assay(ELISA)
Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination
GMFR of pre-F protein-binding antibodies
Measured by enzyme-linked immunosorbent assay(ELISA)
Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination
SCR of pre-F protein-binding antibodies
Measured by enzyme-linked immunosorbent assay(ELISA)
Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination
The frequencies of antigen-specific T cells secreting IL-2 and IFN-γ
Measured by ELISpot assay
Time frame: 14 days, 30 days after vaccination
The frequencies of antigen-specific CD4+ and CD8+ T cells expressing IL-2 and IFN-γ
Measured by ICS assay
Time frame: 14 days, 30 days after vaccination.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.